10X Genomics wins judgment against Vizgen's US antitrust counterclaims
( January 3, 2025, 17:06 GMT | Official Statement) -- MLex Summary: 10X Genomics was granted a summary judgment against Vizgen’s US claims accusing it of attempting to monopolize the market for single-cell spatial transcriptomics products. District Judge Matthew F. Kennelly said that based on the evidence, 10x had no “conscious commitment to a common scheme designed to achieve an unlawful objective." Rather, the evidence with regard to 10x is that its commitment was to the lawful objective of obtaining, and enforcing, an exclusive patent license within a particular field.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.